Skip to main content
. 2015 Jan 20;79(2):330–336. doi: 10.1111/bcp.12506

Table 2.

Percentage of all patients (including those ineligible due to lack of baseline data) with an HbA1c measured in the defined time periods relative to cohort entry date

Baseline 30 days before to 7 days after new drug exposure 8–90 days after new drug exposure Follow-up 91–270 days after new drug exposure
Metformin 61% 46% 72%
Metformin on PPI 66% 48% 74%
PPI 8% 15% 26%
PPI on metformin 23% 36% 63%